Advances in Bladder Preservation Approaches for Bladder Cancer (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 60
Special Issue Editors
Interests: genitourinary cancers; prostate cancer; bladder cancer; head and neck cancer; salivary gland cancer; particle radiotherapy; proton therapy; neutron therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Bladder cancer is the 10th most common cancer worldwide. Surgical management with radical cystectomy and urinary diversion is the primary definitive treatment for most operable patients with muscle-invasive disease. Cystectomy is also a standard salvage therapy for patients with high-risk, non-muscle-invasive disease that is recurrent or persistent after conservative management and intravesical therapy. However, advanced age and medical comorbidities in this patient population often impact surgical candidacy. Many patients also decline cystectomy given the significant quality of life factors related to radical surgery and urinary diversion. Hence, there has been significant interest in non-surgical options for bladder preservation, either as a definitive treatment or to delay the need for cystectomy.
In this Special Issue, we will invite submissions including original research studies and contemporary reviews of current therapeutic strategies advancing the field of bladder preservation for bladder cancer. This may encompass updates on intravesical therapy, the emerging role of systemic therapy, including immunotherapy, and advances in radiotherapy and chemoradiation (trimodality therapy).
Dr. Jay J. Liao
Dr. Todd A. Yezefski
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer
- bladder preservation
- trimodality therapy
- chemoradiation
- immunotherapy
- intravesical therapy
- BCG refractory or unresponsive
